Harvard Bioscience (HBIO) Getting Somewhat Favorable Media Coverage, Report Finds

Media coverage about Harvard Bioscience (NASDAQ:HBIO) has trended somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Harvard Bioscience earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned media headlines about the medical instruments supplier an impact score of 45.552416075827 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Harvard Bioscience (NASDAQ HBIO) opened at $3.30 on Tuesday. The firm has a market capitalization of $118.59, a P/E ratio of 113.33 and a beta of 1.00. Harvard Bioscience has a twelve month low of $2.25 and a twelve month high of $3.90. The company has a current ratio of 3.40, a quick ratio of 1.87 and a debt-to-equity ratio of 0.13.

Harvard Bioscience (NASDAQ:HBIO) last issued its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.03 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.03. The business had revenue of $25.05 million for the quarter, compared to analysts’ expectations of $24.60 million. Harvard Bioscience had a positive return on equity of 1.11% and a negative net margin of 3.16%. research analysts predict that Harvard Bioscience will post 0.05 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Harvard Bioscience (HBIO) Getting Somewhat Favorable Media Coverage, Report Finds” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/05/harvard-bioscience-hbio-getting-somewhat-favorable-media-coverage-report-finds.html.

About Harvard Bioscience

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Insider Buying and Selling by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply